Recent advances on blinatumomab for acute lymphoblastic leukemia

Although complete remission rate of B cell acute lymphoblastic leukemia (B-ALL) has improved significantly over the past few decades, patients with relapsed/refractory ALL still have dismal outcome. Tyrosine kinase inhibitors, antibody–drug conjugates and chimeric antigen receptor T cell therapy are...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Juanjuan, Song, Yongping, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6833142/
https://www.ncbi.nlm.nih.gov/pubmed/31709129
http://dx.doi.org/10.1186/s40164-019-0152-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6833142/
https://www.ncbi.nlm.nih.gov/pubmed/31709129
http://dx.doi.org/10.1186/s40164-019-0152-y

Ejemplares similares